Lecanemab is a monoclonal antibody with high affinity to amyloid-beta soluble protofibrils. It was approved in 2023 as an IV ...

Differences in outcomes between patients with early Alzheimer’s disease who used lecanemab and matched controls increased ...

Four years of lecanemab treatment led to less cognitive decline and potentially even improvement in clinical scores over time, with a favorable safety profile, in the open-label extension trial.

A health ministry panel Wednesday approved a plan to cut the price of Lecanemab, an Alzheimer's drug codeveloped by Japanese ...

Lecanemab and donanemab effects lasting over three years, new treatments, trials of home injections and blood tests for ...

Tokyo, Aug. 6 (Jiji Press)--A Japanese health ministry panel Wednesday approved a plan to cut the price of Lecanemab, an ...

Seven years of investigation by scientists at Harvard Medical School has revealed that the loss of the metal lithium plays a ...

A 10-year study in Nature shows lithium levels drop early in dementia; tiny doses of lithium orotate were effective in mice.

Erin Kelly is likely going to forget her eight-year-old daughter Evie’s name before her little girl finishes high school.

Subtyping is what made precision medicine in cancer a reality. And for successful drug discovery in all its stages, finding ...

Alzheimer's disease is the most common type of dementia. All types of dementia involve a gradual loss of functions such as ...

New findings presented at the 2025 Alzheimer’s Association International Conference (AAIC) in Toronto spotlighted the long-term potential of two FDA-approved Alzheimer’s treatments for people with ...